



Research Article

ISSN : 0975-7384
CODEN(USA) : JCPRC5

Synthesis of some benzoxazole derivatives and their anti-inflammatory evaluation

Khaled R. A. Abdellatif ^a, Noha H. Amin ^b and Asmaa A. Mohammed ^{b*}

^aDepartment, of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef, Egypt

^bDepartment of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

ABSTRACT

Novel series of benzo-oxazole derivatives were prepared by the condensation of 4- methyl sulfonyl acetophenone with various benzamide. The structures of the synthesized compounds were VII-VI3 assigned on the basis of elemental analysis, IR, ¹H NMR and mass spectroscopy. These compounds were screened for anti-inflammatory activity having as insignificant anti-inflammatory activity when compared to the reference anti-inflammatory drug celecoxib using *In vivo* and *In vitro* anti-inflammatory screening

Key words: Benzo-oxazole, Carrageenan - induced rat paw edema, Anti-inflammatory activity.

INTRODUCTION

Benzo-oxazole is an aromatic organic compound with a molecular formula C₇H₅NO, benzene fused oxazole ring structure, and an odour similar to pyridine. Benzo-oxazole is used primarily in industry and research, and has no household use. Being a heterocyclic compound, benzo-oxazole finds use in research as a starting material for the synthesis of larger, usually bioactive structures. It is found within the chemical structures of pharmaceutical drugs such as Flunoxapropfen. Its aromaticity makes it relatively stable, although as a heterocyclic, it has reactive sites which allow for functionalization. Oxazole and its derivatives are used as building blocks for biochemicals and pharmaceuticals as well as in other industrial applications such as pesticides, dyes, fluorescent brightening agents, textile auxiliaries and plastics.:

General structure of benzo-oxazole

Benzo-oxazoles are an important class of heterocyclic compounds that have many applications in medicinal chemistry. For example, benzo-oxazole derivatives have been characterized as melatonin receptor agonists,¹⁷ amyloidogenesis inhibitors,¹⁸ Rho kinase inhibitors,¹⁹ and antitumor agents.²⁰ In addition to their use in medicinal chemistry, benzoxazoles are recognized as an important scaffold in fluorescent probes such as anion and metal cation sensors.²¹ Benzoxazoles are an important class of heterocycles that are encountered in a number of natural products and are used in drug and agrochemical discovery programs, as well as for a variety of other purposes. For example, the benzoxazole core structure is found in a variety of cytotoxic natural products, such as the UK-1,²² AJI9561,²³ and salvianen.²⁴ Recent medicinal chemistry applications of benzoxazoles include the cathepsin S inhibitor,²⁵ selective peroxisome proliferator-activated receptor γ antagonist JTP-426467.²⁶ Other applications of benzoxazoles include their use as herbicides, such as Fenoxaprop, and as fluorescent whitening agent dyes such as bisbenzoxazolylenes and arenes. Mainly there are two general methods for synthesizing 2-

substituted benzoxazoles, benzimidazoles, and benzothiazoles. One is the coupling of *o*-substituted aminoaromatics with carboxylic acid derivatives and acyl chlorides, which is either catalyzed by strong acids or microwave conditions. The other is the oxidative cyclization of Phenolic Schiff bases derived from the condensation of *o*-substituted aminoaromatics and aldehydes. In latter reactions various oxidants have been used. Different catalysts and different methods were also reported for the synthesis of these heterocycles.

Pang Yi et al., 42 described the synthesis of substituted benzoxazoles by using palladium mediated oxidative cyclization.

Wang Shen et al., 43 described an efficient method for the synthesis of substituted benzimidazoles from 1,1-dibromoethenes and *o*-diaminobenzenes. The reaction employs DABCO as the base and NMP as the solvent. developed a new and efficient method for the preparation of benzoxazoles[4,5-*b*]pyridines from reactions of orthoesters with *o*-substituted aminoaromatics and 2-amino-3-hydroxypyridine in the presence of catalytic amounts of the moisture stable, inexpensive $ZrOCl_2 \cdot 8H_2O$ under solvent-free conditions.

Mohammadpoor-Baltork et al., 45 described an efficient method for the preparation of benzoxazoles, benzimidazoles and oxazolo[4,5-*b*]pyridines from reactions of orthoesters with *o*-substituted aminoaromatics and 2-amino-3-hydroxypyridine in the presence of silica sulfuric acid under heterogeneous and solvent-free conditions.

N. Sekar et al., 46 developed a protocol for the preparation of benzimidazoles, benzoxazoles, and benzothiazoles from reactions of aldehydes with *o*-substituted aminoaromatics in the presence of catalytic amount of Indion 190 resin in ethanol solvent at 70°C and obtained high yields of the products. *Chapter -2 Benzoxazole*,

John Blacker et al., 47 developed ruthenium-catalyzed hydrogen-transfer reactions for the conversion of alcohols and aldehydes into benzoxazoles

K.V.Srinivasan et al., 48 described a regioselective one-pot synthesis of 2-arylbenzimidazoles, benzoxazoles and benzothiazoles and isolated high yields of products under ambient conditions using the ionic liquids, 1-butylimidazolium tetrafluoroborate ([Hbim]BF₄) and 1,3-di-*n*-butylimidazolium tetrafluoroborate ([bbim]BF₄) as reaction media and promoters.

A. K. Chakraborti et al., 49 reported an efficient conversion of carboxylic acids to benzothiazoles by direct condensation with 2-aminothiophenol under microwave irradiation in the absence of solvent.

A. K. Chakraborti et al., 50 described a method for direct coupling of carboxylic acids with 2-aminophenol under microwave conditions to get 2-substituted benzoxazoles under metal and solvent-free conditions.

A. K. Chakraborti et al., 51 described that methanesulphonic acid has been found to be a highly effective catalyst for a convenient and one-pot synthesis of 2-substituted benzoxazoles by the reaction of 2-aminophenol with acid chlorides.

T. Punniyamurthy et al., 52 developed a method for copper(II)-catalyzed conversion of bisaryloxime ethers to 2-arylbenzoxazoles. The reaction involves a cascade C-H functionalization and C-N/C-O bond formation under oxygen atmosphere.

T. Punniyamurthy et al., 53 reported a synthesis of substituted benzimidazoles, 2-aminobenzimidazoles, 2-aminobenzothiazoles, and benzoxazoles via intramolecular cyclization of *o*-bromoaryl derivatives using copper(II) oxide nanoparticles in DMSO under air.

P. T. Perumal et al., 54 reported that Pyridinium chlorochromate (PCC) supported on silica gel effects the oxidative cyclization of structurally diverse thiophenolic and Phenolic Schiff's bases, thereby providing an efficient and convenient method for the synthesis of a library of 2-arylbenzothiazoles and 2-arylbenzoxazoles.


M. R. Player et al., 55 developed for synthesis of benzoxazoles by using microwave assisted dielectric heating.

Masahiko Hayashi *et al.*,⁵⁶ described that 2-arylbenzoxazoles were directly synthesized from substituted 2-aminophenols and aldehydes in the presence of activated carbon (Darco KB) in Xylene under an oxygen atmosphere. Wang, Lei *et al.*,⁵⁷ reported for the synthesis of benzoxazole derivatives through the reaction of substituted 2-aminophenols and acyl chlorides in the presence of catalytic amount of In(OTf)₃ under solvent-free reaction conditions. S. C. Shim *et al.*,⁵⁸ reported that 2-amino phenols react with an array of carboxylic acids in Dioxane at 180°C in the presence of tin(II)chloride to afford the corresponding 2-substituted benzoxazole in good yields.

EXPERIMENTAL SECTION

2.1. Chemistry:

All melting points are corrected and determined by the open capillary method using IA9100MK- Digital Melting Point Griffin Apparatus. Infrared spectra were made on BRUKER Vector 22 (Japan), infrared spectrophotometers and were expressed in wavenumber (cm⁻¹) using potassium bromide disc, at the microanalytical Center, Faculty of Science, Cairo University. The proton magnetic resonance ¹H-NMR and carbon magnetic resonance ¹³C-NMR were recorded on a Bruker Avance III 400 MHz for ¹H and 100 MHz for ¹³C (Bruker AG, Switzerland) with BBFO Smart Probe and Bruker 400 AEON Nitrogen-Free Magnet. Mass spectra were recorded on Fennigan MAT, SSQ 7000, Mass spectrometer, at 70 eV (EI) at the microanalytical Center, Faculty of Science, Cairo University and Waters Micromass Q-ToF Micro mass spectrometer (ESI) and Waters Acquity Ultra Performance LC with ZQ detector in ESI mode. All the compounds were named according to the IUPAC system using CS Chem. Draw Ultra version 12.0. Thin layer chromatography, using Macherey–Nagel AlugramSil G/UV254 silica gel plates and ethyl acetate-hexane as the eluting system.



number	Code	COX1 μm IC 50	COX2 μm IC 50
1-	Celecoxib	14.8	0.05
V1	Acetamide	3.41	.33
V2	Chloro phenyl oxazole	7.11	.69
V3	Amino phenyl oxzole	6.97	.81

2.1.1. General method for preparation of (4-(methyl sulfonyl)phenyl)oxazole(VI-V3)

Amide(.145g,.898 mmol) and (methyl sulfonyl)benzoyl bromide (200 g,.749mmol) were placed in a sealed tube and heated at 150°C for 4 h. The reaction mixture was quenched with ethyl acetate and the residue was purified by column chromatography (gradient 100;1,20:1 hexane:dichloromethane).The Product was further Purified by Preparative-TLC(100:1,hexane:dichloromethane)to yield 0.0148 g(5%) of the Title compound as a white solid. 2-methyl-4-(4-(methyl sulfonyl)phenyl)oxazole (V1) yield 60%; mp:190-200°C.¹H-NMR (DMSO-d₆) δ ppm:3.1(s,3H,SO₂CH₃),2.35(s,3H,CH₃),7.5(s,1H,CH),7.99(d,2H,c2,6),7.76,(d,2H,c3,5).¹³C-NMR (DMSO-d₆) δ ppm:44,3(SO₂CH₃),138,9(C1),128,8(c2,6),128,5(c3,5),138.1(C6),oxazole ring 165(c2),139,9(C4).140.1(c5),14,2(CH₃)2-(4-chlorophenyl)-4-(4-(methyl sulfonyl)phenyl)oxazole (V2) Yield 70%; mp:170-180°C.¹H-NMR (DMSO-d₆) δ ppm:3.1(s,3H,SO₂CH₃),7.5(s,1H,CH),7.99(d,2H,c2,6),7.76,(d,2H,c3,5),7.42(d,2H,C2,6)7.33(d,2H,C3,5).¹³C-NMR (DMSO-d₆) δ ppm:44,3(SO₂CH₃),138,9(c1),128,8(c2,6),128,5(c3,5),138.1(C6),oxazole ring 165(c2),139,9(C4).140.1(c5)benzene.129.1(c4,6),116(c1,3),162,9(c2),121.8(c5)4-(4-(4-(methyl sulfonyl)phenyl)oxazole-2-yl)benzenamine(V3) Yield 55%; mp:145-150°C.¹H-NMR (DMSO-d₆) δ ppm:3.1(s,3H,SO₂CH₃),7.5(s,1H,CH),7.99(d,2H,c2,6),7.76,(d,2H,c3,5),7.23(d,2H,c2,6),6.52(d,2H,c3,5),11(2H,NH₂).¹³C-NMR (DMSO-d₆) δ ppm:44,3(SO₂CH₃),138,9(c1),128,8(c2,6),128,5(c3,5),138.1(C6),oxazole ring 159(c2),139,9(C4).140.1(c5)benzene.116.8(C2,6),128.3(c3,5),116.2(c4),148,4(c1)

2.2. Antiinflammatory activity**BY COX Inhibitor screening assay kit****• Materials Needed**

1. A plate reader capable of measuring absorbance between 405-420 nm.
2. Adjustable pipettes and a repeat pipettor.
3. A source of 'UltraPure' water. Water used to prepare all EIA reagents and buffers must be deionized and free of trace organic contaminants ('UltraPure'). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for EIA. NOTE: UltraPure water is available for purchase from Cayman (Item No. 400000).
4. A 37°C water bath that can hold a test tube rack.
5. Disposable glass test tubes (13 mm x 100 mm).
6. Materials used for purification procedure

About This Assay

The COX (ovine) Inhibitor Screening Assay directly measures PGF_{2a} by SnCl₂ reduction of COX-derived PGH-, produced in the COX reaction. The prostanoid product is quantified via enzyme immunoassay (EIA) using a broadly specific antiserum that binds to all the major PG compounds.

This assay includes both ovine COX-1 and human recombinant COX-2 enzymes allowing the user to screen isozyme-specific inhibitors. This assay is an excellent tool which can be used for general inhibitor screening, or to eliminate false positive leads generated by less specific methods.

COX REACTION PROCEDURE

The use of both enzymes is not a requirement of the assay; one or both enzymes may be used depending on the nature of the study. The EIA plate will allow for 36 COX reactions (in duplicate) at one dilution or 18 COX reactions (in duplicate) at two dilutions.

IMPORTANT: Please read both COX Reaction Procedure and EIA Procedure sections carefully before initiating your experiments!

COX Reagent Preparation

1. Reaction Buffer (10X) - (Item No. 460104)

Dilute 5 ml of Reaction Buffer concentrate with 45 ml of UltraPure water. This final Reaction Buffer (0.1 M Tris-HCl, pH 8.0, containing 5 mM EDTA and 2 mM phenol) is used in the COX reactions and for dilution of Heme. When stored at room temperature, this diluted Reaction Buffer is stable for at least one month. Equilibrate the diluted Reaction Buffer to 37°C before using in the COX reactions.

2. COX-1 (ovine) - (Item No. 460100)

This vial contains a solution of ovine COX-1. To avoid repeated freezing and thawing, the COX-1 should be aliquoted into several small vials and stored at -80°C. The enzyme is ready to use as supplied and should be kept on ice when thawed. There is enough COX-1 supplied to perform 40 reactions.

3. COX-2 (human recombinant) - (Item No. 460121)

This vial contains a solution of human recombinant COX-2. To avoid repeated freezing and thawing, the COX-2 should be aliquoted into several small vials and stored at -80°C. The enzyme is ready to use as supplied and should be kept on ice when thawed. There is enough COX-2 supplied to perform 40 reactions.

4. Heme - (Item No. 460102)

This vial contains a solution of Heme in dimethylsulfoxide (DMSO). Dilute 100 pi of Heme with 400 pi of IX Reaction Buffer prior to use. The diluted Heme is stable for 12 hours at room temperature.

5. Arachidonic Acid (Substrate) - (Item No. 460103)

This vial contains a solution of Arachidonic Acid in ethanol. Transfer 50 pi of the supplied Substrate to another vial, add 50 pi of Potassium Hydroxide (Item No. 460105), vortex, and dilute with 400 pi of UltraPure water to achieve a final concentration of 10 mM. Use the prepared Arachidonic Acid Solution within one hour. A 10 pi aliquot of the prepared substrate will yield a final concentration of 100 pM in the reaction.

6. Potassium Hydroxide - (Item No. 460105)

This vial contains 0.1 M Potassium Hydroxide (KOH). The reagent is ready to use as supplied.

7. Hydrochloric Acid - (Item No. 460106)

This vial contains 1 M Hydrochloric Acid (HCl). Dilute 500 pi with 4.5 ml of UltraPure water to yield a concentration of 0.1 M. This diluted HCl is used to prepare the saturated Stannous Chloride Solution. Both HCl solutions are stable for at least one month at room temperature.

8. Stannous Chloride - (Item No. 460107)

This vial contains crystalline Stannous Chloride. Add 5 ml of 0.1 M HCl and vortex to produce a saturated solution of Stannous Chloride. (This saturated Stannous Chloride Solution may be cloudy.) This solution is stable for eight hours at room temperature. If not performing all of the COX reactions in one day, weigh 125 mg of Stannous Chloride into another vial and add 2.5 ml of 0.1 M HCl. 100 pi of saturated Stannous Chloride is required for each reaction. NOTE: Stannous Chloride is used to reduce PGEI₂, produced in the COX reaction, to a more stable PC, PGF_{2cc} Performing COX Reactions

Pipetting Hints

- It is recommended that a repeating pipettor be used to deliver Arachidonic Acid to the test tubes. This saves time and helps to maintain more precise incubation times.
- Use different tips to pipette the buffer, enzyme, Heme, inhibitor, and Arachidonic Acid.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (i.e., slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the test tube.

5. COX-2 Inhibitor tubes - add 950 pi of Reaction Buffer, 10 pi of Heme, and 10 pi of COX-2 to six test tubes.

6. Add 20 pi of inhibitor to the COX-1 and -2 inhibitor tubes and 20 pi of Reaction Buffer or solvent to the 100% Initial Activity tubes and vortex.

7. Incubate for 10 minutes at 37°C. NOTE: The incubation of the enzymes with the inhibitor can be between 10 and 20 minutes without affecting enzyme stability, but the incubation time MUST be the same for all samples in an individual experiment.

8. Initiate the reaction by adding 10 pi of Arachidonic Acid to all the test tubes. Vortex and incubate for another two minutes at 37°C.

9. Add 50 pi of 1 M HCl to each test tube to stop enzyme catalysis. Remove test tubes from the water bath, add 100 pi of the saturated Stannous Chloride Solution to each test tube and vortex. Incubate for five minutes at room temperature. The reaction mixture will be cloudy.

Preparation of the Data

The following procedure is recommended for preparation of the data prior to graphical analysis.

NOTE: If the plate reader has not subtracted the absorbance readings of the blank wells from the absorbance readings of the rest of the plate, be sure to do that now.

1. Average the absorbance readings from the NSB wells.
2. Average the absorbance readings from the B0 wells.
3. Subtract the NSB average from the B0 average. This is the corrected B0 or corrected maximum binding.
4. Calculate the %B/B0 (% Sample or Standard Bound/Maximum Bound) for the remaining wells. To do this, subtract the average NSB absorbance from the Si absorbance and divide by the corrected B0 (from Step 3). Multiply by 100 to obtain %B/Bq. Repeat for S2-S8 and all sample wells.

NOTE: The total activity (TA) values are not used in the standard curve calculations. Rather, they are used as a diagnostic tool; the corrected Bg divided by the actual TA (10X measured absorbance) will give the % Bound. This value should closely approximate the % Bound that can be calculated from the Sample Data (see page 25). Erratic absorbance values and a low (or no) % Bound could indicate the presence of organic solvents in the buffer or other technical problems (see page 31 for Troubleshooting).

If you have purified your samples (see Interference, page 29), the final sample concentrations can be determined
Plot the Standard Curve

Plot %B/B0 for standards S1-S8 versus Prostaglandin concentration using linear (y) and log (x) axes and perform a 4-parameter logistic fit.

Alternative Plot - The data can also be linearized using a logit transformation. The equation for this conversion is shown below. NOTE: Do not use %B/Bg in this calculation.

$$\text{logit (B/B0)} = \ln [B/B0/(1 - B/B0)]$$

Plot the data as logit (B/B0) versus log concentrations and perform a linear regression fit.

RESULTS AND DISCUSSION

3.1. Chemistry

The synthetic approaches adopted to obtain the target compounds v1-v3 were depicted in scheme 1. The structures of the newly synthesized compounds were established on the basis of their elemental analyses and spectral data bromoacetophenone was the key starting material for the new oxazole derivatives V1-V3. They were synthesized in good yields upon the fusion of amide b and bromoacetophenone a for 8 hrs. The ¹H-NMR of These compounds showing 8.1 (CH)

3.2. Anti-inflammatory screening

All the 3 newly synthesized compounds (10mg/ml) were screened for anti-inflammatory activity using Cox1, Cox2

CONCLUSION

The newly synthesized compounds V1-V3 presented here differed in their corresponding anti-inflammatory activity depending on the type of the derivative hybridized to the benzo oxazole moiety. The derivative having the electron withdrawing Cl group at the p-position of benzene ring attached at the 2-position of oxazole ring showed the highest activity.

REFERENCES

- [1] McKee, M. L.; Kerwin, S. M. *Bioorg. Med. Chem.* **2008**, 16, 1775.
- [2] Mortimer, C. G.; Wells, G.; Crochard, J. P.; Stone, E. L.; Bradshaw, T. D.; Stevens, M. F. G.; Westwell, A. D. J. *Med. Chem.* **2006**, 49, 179.

- [3] Grobler, J. A.; Dornadula, G.; Rice, M. R.; Simcoe, A. L.; Hazuda, D. J.; Miller, M.D. *J. Biol. Chem.* **2007**, 282, 8005.
- [4] Rasmussen, K.; Hsu, M. A.; Yang, Y. *Neuropsychopharmacology.* **2007**, 32, 786.
- [5] Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. *Org. Biomol. Chem.* **2006**, 4,2337.
- [6] Evans, D.A.; Sacks, C.E.; Kleshick, W.A.; Taber, T.R. *J.Am.Chem.Soc.* **1979**, 101,6789-6791.
- [7] Yamato, M. *J. Pharm. Soc. Jpn.* **1992**, 112, 81-99.
- [8] Song, X.; Vig, B.S.; Lorenzi, P.L.; Darch, J.C.; Townsend, L.B.; Amidon, G.L. *J.Med. Chem.* **2005**, 48, 1274-1277.
- [9] Kumar, D.; Jacob, M.R.; Reynolds, M.B.; Kerwin, S.M. *Bioorg. Med. Chem.* **2002**,10, 3997-4004.
- [10] Yildiz-Oren, I.; Yalcin, I.; Aki-Sener, E.; Ucarturk, N. *Eur. J. Med. Chem.* **2004**,39, 291-298.*Chapter -2 Benzoxazole, benzimidazole*[108]
- [11] Benazzou, A.; Boraund, T.; Dubedat, P.; Boireau, J.M.; Stutzmann, C. *Eur. J.Pharmacol.* **1995**, 284, 299-307.
- [12] Figge, A.; Altenbach, H.J.; Brauer, D.J.; Tielmann, P. *Tetrahedron Asymmetr.***2002**, 13, 137-144.
- [13] Scott, L.J.; Dunn, C.J.; Mallarkey, G.; Sharpe, M. *Drugs* **2002**, 62, 1503-1538.
- [14] Nakano, H.; Inoue, T.; Kawasaki, N.; Miyataka, H.; Matsumoto, H.; Taguchi, T.; Inagaki, N.; Nagai, H.; Satoh, T. *Bioorg. Med. Chem.* **2000**, 8, 373-380.
- [15] Zhu, Z.; Lippa, B.; Darch, J.C.; Townsend, L.B. *J. Med. Chem.* **2000**, 43, 2430-2437.
- [16] Zarrinmayeh, H.; Nunes, A.M.; Ornstein, P.L.; Zimmerman, D.M.; Arnold, M.B.; Schober, D.A.; Gackenheimer, S.L.; Bruns, R.F.; Hipskind, P.A.; Britton, T.C.; Cantrell, B.E.; Gehlert, D.R. *J. Med. Chem.* **1998**, 41, 2709-2719.
- [17] Sun, L. Q.; Chen, J.; Takaki, K.; Johnson, G.; Iben, L.; Mahle, C. D.; Ryan, E.; Xu, C. *Bioorg. Med. Chem. Lett.* **2004**, 14, 1197.
- [18] Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W. *J. Med. Chem.* **2008**, 51,260.
- [19] Sessions, E. H.; Yin, Y.; Bannister, T. D.; Weiser, A.; Griffin, E.; Pocas, J.; Cameron, M. D.; Ruiz, C.; Lin, L.; Schuerer, S. C.; Schroeter, T.; LoGrasso, P.; Feng, Y. *Bioorg. Med. Chem. Lett.* **2008**, 18, 6390.*Chapter -2 Benzoxazole, benzimidazole*[109]
- [20] RidaSamia, M.; AshourFawzia, A.; El-Hawash Soad, A. M.; ElSemaary Mona, M.; Badr Mona, H.; Shalaby Manal, A. *Eur. J. Med. Chem.* **2005**, 40, 949.
- [21] Taki, M.; Wolford, J. L.; O Halloran, T. V. *J. Am. Chem. Soc.* **2004**, 126, 712.
- [22] Ueki, M.; Ueno, K.; Miyadoh, S.; Abe, K.; Shibata, K.; Taniguchi, M.; Oi, S. *J. Antibiot.* **1993**, 46, 1089.
- [23] Sato, S.; Kajjura, T.; Noguchi, M.; Takehana, K.; Kobayashi, T.; Tsuji, T. *J. Antibiot.* **2001**, 54, 102.
- [24] Don, M. J.; Shen, C. C.; Lin, Y. L.; Syu Jr, W.; Ding, Y. H.; Sun, C. M. *J. Nat. Prod.***2005**, 68, 1066.
- [25] Tully, D. C.; Liu, H.; Alper, P. B.; Chatterjee, A. K.; Epple, R.; Roberts, M. J.; Williams, J. A.; Nguyen, K. T.; Woodmansee, D. H.; Tumanut, C.; Li, J.; Spraggon, G.; Chang, J.; Tuntland, T.; Harris, J. L.; Karanewsky, D. S. *Bioorg. Med. Chem. Lett.***2006**, 16, 1975.
- [26] Nishiu, J.; Ito, M.; Ishida, Y.; Kakutani, M.; Shibata, T.; Matsushita, M.; Shindo, M. *Diabetes Obes. Metab.* **2006**, 8, 508.
- [27] Leaver, I. H.; Milligan, B. *Dyes Pigm.* **1984**, 5, 109.
- [28] Barker, H. A.; Smyth, R. D.; Weissbach, H.; Toohey, J. I.; Ladd, J. N.; Volcani, B.E. *J. Biol. Chem.* **1960**, 235, 480-488.
- [29] Sih J.C., Im W.B., Robert A., Graber D.R., Blackmann D.P., *J.Med. Chem.*, **1991**,34, 1049 -1062.
- [30] Kuhler T.C., Fryklund J., Bergman N., Weilitz J., Lee A., and Larsson H., *J.Med.Chem.*, **1995**, 38, 4906-4916. *Chapter -2 Benzoxazole, benzimidazole*[110]
- [31] Carcanagu D, Shue Y.K., Wuonola M.A., Nickelsen M.U., Joubran C., Abedi J.K., Jones J., Kuhler T.C., *J. Med. Chem.*, **2002**, 45, 4300-4309.
- [32] Seth S.D., *Text Book of Pharmacology*, 2nd ed; Elsevier, New Delhi, **1999**, 390-391.
- [33] Murthi, Y.; Pathak, D. *J Pharm Res.* **2008**, 7(3), 153-155.
- [34] Hutchinson, I.; Chua, M. S.; Browne, H. L.; Trapani, V.; Bradshaw, T. D.; Westwell, A. D. *J Med Chem.* **2001**, 44,1446-1449.
- [35] Sreenivasa, M.; Jaychand, E.; Shivakumar, B.; Jayraj Kumar, K.; Vijaykumar, J. *Arch Pharm Sci and Res.* **2009**, 1(2), 150-157.
- [36] Henriksen, G.; Hauser, A. I.; Westwell, A. D.; Yousefi, B. H.; Schwaiger, M.; Drzezga, A.; Wester, H. J. *J. Med. Chem.* **2007**, 50, 1087.
- [37] Black, C.; Deschenes, D.; Gagnon, M.; Lachance, N.; Leblanc, Y.; Leger, S.; Li, C.S.; Oballa, R. M. *PCT Int. Appl.* **2006**, WO 2006122200 A1 20061116.

- [38] Bradshaw, T. D.; Wrigley, S.; Shi, D. F.; Schulz, R. J.; Paull, K. D.; Stevens, M. F.G. *Br. J. Cancer* **1998**, 77, 745.
- [39] Lau, C. K.; Dufresne, C.; Gareau, Y.; Zamboni, R.; Labelle, M.; Young, R. N.; Metters, K. M.; Rochette, C.; Sawyer, N.; Slipetz, D. M. L.; Jones, C. T.; McAuliffe, M.; McFarlane, C.; Ford-Hutchinson, A. W. *Bioorg. Med. Chem.* **1995**, 5, 1615.
- [40] Bergman, J. M.; Coleman, P. J.; Cox, C.; HartmanLindsley, G. D. C.; Mercer, S.P.; Roecker, A. J.; Whitman, D. B. *PCT Int. Appl.* **2006**, WO 2006127550.
- [41] Ali, A.; Taylor, G. E.; Graham, D. W. *PCT Int. Appl.* **2001**, WO 2001028561.
- [42] Pang Y.; Hua, W. *Tetrahedron Lett.* **2009**, 50, 6680-6683.1. Nugteren, D.H. and Hazelhof, E. *Biochim. Biophys. Acta* 326, 448-461 (**1973**).
- [43] Hamberg, M. and Samuelsson, B. *Proc. Natl. Acad. Sci. USA* 70, 899-903 (**1973**).
- [44] Xie, W., Chipman, J.G., Robertson, D.L., et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc. Natl. Acad. Sci. USA* 88, 2692-2696 (**1991**).
- [45] Blobaum, A.L. and Marnett, L.J. *Med. Chem.* 50(7), 1425-1441 (**2007**).
- [46] Maclouf, J., Grassi, J., and Pradelles, P. Development of enzyme-immunoassay techniques for the measurement of eicosanoids, Chapter 5, in *Prostaglandin and Lipid Metabolism in Radiation Injury*. Walden, T.L., Jr. and Elughes, H.N., editors, Plenum Press, Rockville, 355-364 (**1987**).
- [47] Pradelles, P., Grassi, J., and Maclouf, J.A. *Anal. Chem.* 57, 1170-1173 (**1985**)